(NASDAQ: PHVS) Pharvaris Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.
Pharvaris Nv's earnings in 2025 is -$195,689,775.On average, 13 Wall Street analysts forecast PHVS's earnings for 2025 to be -$157,226,682, with the lowest PHVS earnings forecast at -$162,536,175, and the highest PHVS earnings forecast at -$128,166,786. On average, 13 Wall Street analysts forecast PHVS's earnings for 2026 to be -$152,940,772, with the lowest PHVS earnings forecast at -$164,057,865, and the highest PHVS earnings forecast at -$138,741,983.
In 2027, PHVS is forecast to generate -$111,603,357 in earnings, with the lowest earnings forecast at -$151,271,292 and the highest earnings forecast at -$81,038,192.